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Abstract: The gut microbiota has emerged as an environmental contributor to colorectal cancer
(CRC) in both animal models and human studies. It is now generally accepted that bacteria
are ubiquitous colonizers of all exposed human body surfaces, including the entire alimentary
tract (5). Recently, the concept that a normal bacterial microbiota is essential for the development
of inflammation-induced carcinoma has emerged from studies of well-known colonic bacterial
microbiota. This review explores the evidence for a role of fusobacteria, an anaerobic gram-negative
bacterium that has repeatedly been detected at colorectal tumor sites in higher abundance than
surrounding histologically normal tissue. Mechanistic studies provide insight on the interplay
between fusobacteria, other gut microbiota, barrier functions, and host responses. Studies have
shown that fusobacteria activate host inflammatory responses designed to protect against pathogens
that promote tumor growth. We discuss how future research identifying the pathophysiology
underlying fusobacteria colon colonization during colorectal cancer may lead to new therapeutic
targets for cancer. Furthermore, disease-protective strategies suppressing tumor development by
targeting the local tumor environment via bacteria represent another exciting avenue for researchers
and are highlighted in this review.
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1. Introduction
There are an estimated 142,820 new cases of colorectal cancer (CRC) annually in the United States,
with over 50,000 deaths [1]. Researchers have established the major risk factors of CRC. American
males have 25% higher risk of CRC than females, and African Americans have 20% higher incidence
than Caucasians. Age is also a risk factor, with less than 10% of cases occurring under the age of 50 [2].
Colorectal carcinomas are classified by etiology as inherited (e.g., hereditary nonpolyposis
colorectal cancer due to genetic instability and familial adenomatous polyposis (FAP) coli due to
a mutation in the adenomatous polyposis coli gene, APC), inflammatory (e.g., Crohn’s disease and
ulcerative colitis), or sporadic [2]. Over 80% of CRCs are classified as sporadic CRC and these have
a poorly defined etiology. Sporadic tumorigenesis is thought to involve mutations in the APC (5q),
DNA hypomethylation, and multiple epigenetic changes, notably in KRAS2 (12p), DCC (18q), and p53
(17p) [3].
As well as genetic factors, there are environmental factors that increase the risk of CRC.
In particular, diet has been associated with CRC. Previous studies have established that consumption
of red and processed meats, highly refined carbohydrates, and alcohol carry an increased risk of
CRC [4].
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The gut microbiota has emerged as an environmental promoter of CRC in both animal models and
human studies, which is the focus of discussion from here onward. It is now generally accepted
that bacteria are ubiquitous colonizers of the human body, including along the gastrointestinal
tract [5]. These bacterial communities are established at birth, and a lifelong symbiotic relationship
forms, with the human providing nutrients. In return, bacteria are involved in many processes,
including tempering immune responses, metabolizing food and byproducts, and preventing
pathogenic bacterial diseases. The concept that normal bacterial microbiota plays a role in the
development of inflammation-induced cancer has gained prominence from the considerable colonic
microbiota literature.
2. Microbiome and Colorectal Carcinogenesis
Despite large interpersonal variability, it is known that an average colorectal microbiota
includes anaerobic bacteria, including Bacteroides, Eubacterium, Bifidobacterium, Fusobacterium,
Peptostreptococcus, and Atopobium [6,7]. Facultative anaerobes include Lactobacilli, Enterococci, Streptococci,
and Enterobacteriaceae are also usually present at about 1000-fold lower abundance [6]. However,
an individual’s microbiota is influenced by diet, age, gender, and ethnicity, and its dynamic nature
makes it difficult to characterize [7]. From the 1990s onward, studies emerged demonstrating
associations between colon cancer and specific bacterial species found in fecal or mucosal tissue
samples, including Streptococcus bovis, Bacteroides, and Clostridia [6,8,9].
Chen et al. undertook 16S metagenomic profiling to characterize the microbiota present in the
intestinal lumen and mucosa of patients with CRC compared to healthy controls. Bifidobacterium,
Faecalibacterium, and Blautia were attenuated in CRC patients, whereas Porphyromonas and
Mogibacterium were increased [10]. In the lumen, Erysipelotrichaceae, Prevotellaceae, and Coriobacteriaceae
were increased in CRC patients. This suggests that intestinal lumen microbiota may interact with the
host to increase CRC risk [10].
In a study by Shen et al., sequencing 21 adenoma and 23 nonadenoma subjects showed enriched
Proteobacteria and reduced Bacteroidetes in cancer tissue [11]. Sobhani et al. analyzed stool bacterial
DNA using PCA and found Bacteroides/Prevotella species to be more abundant in cancer patients than
in control subjects [12]. These sequencing studies have demonstrated the occurrence of gut microbiota
alterations in CRC.
Fusobacteria, anaerobic gram-negative rods, are rare agents of severe human diseases [13] that
have recently been the center of academic debate after researchers repeatedly noted their link to CRC.
F. nucleatum (Fn) and F. necrophorum are the commonly encountered members of the Fusobacterium
species. They commonly inhabit the oral cavity, occasionally causing periodontal and gingival
infections [14]. The rest of the chapter explores the evidence for the role of Fn in CRC.
3. Clinical Significance of Fn in CRC
Fn buildup in colorectal carcinoma tissue compared to healthy gut tissue was first reported in
2011 by two research groups [15,16]. They found that the abundance of Fn in CRC was significantly
higher than in histologically normal tissue adjacent to the tumor. The difference is also evident in
stool samples [17,18]. Fn enrichment has also been observed in colorectal adenoma, the precursor of
CRC [18,19]. This has led to fecal Fn measurement being touted as a useful predictive marker in the
clinical management of CRC [20].
Several metagenomics-sequencing studies have shown that increased Fn abundance was
positively associated with CRC mortality. For example, one study found CRC patients with high
fusobacterial levels had significantly lower overall survival than patients with average levels of Fn
(p = 0.008) [18]. This would suggest that the enrichment of Fn in CRC tissue could serve as a prognostic
biomarker [18,20,21]. Studies have also demonstrated a positive association between increased amounts
of Fn and CRC metastases, such as hepatic metastatic disease [15,20,22]. These findings indicate that
Fn-high CRC maybe be a clinically relevant subtype of CRC that promotes tumor progression. However,
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several studies did not identify an association between Fn and CRC prognosis [23–25]. There are still
many gaps in our understanding of the role of Fn in CRC and, hence, Fn as a prognostic marker.
4. Translocation of Fn from the Oral Cavity
How Fn colonizes the colon from the mouth is not yet known. Several studies have reported
that microbial colonizers of the oral cavity predict the microbial composition of the gut and vice
versa [26,27]. This suggests the oral cavity may act as a repository for Fn, which is then swallowed to
the gut.
Fn is a major cause of periodontal disease, but epidemiological studies linking periodontal disease
and CRC have been inconclusive. Momen-Heravi et al. (2017) described the increased risk of CRC in a
large cohort study [28], while a separate study found no association between the amount of Fn in the
oral cavity and CRC [29].
Meyerson et al. (2017) showed that Fn colonization of CRC is conserved in nonadjacent
liver metastases, indicating microbiome similarities between paired primary–metastatic tumors [30].
This suggests that Fn might form a symbiotic association with the tumor during metastasis via
lymphatic or hematogenous pathways.
There is also uncertainty about where Fn is found within the colon. Notably, Fn has been
observed principally in proximal colon cancer, with moderately increasing proportions of Fn-high
CRC detected on the right side, from rectum to cecum [24,31]. However, this effect was not seen in
other experiments [32]. These observations are complicated by the fact that right colon cancer exhibits
mucus-invasive bacterial biofilms, which can display blooms of Fn [32].
Overall, there are no conclusive data to support the hypothesis that the origin of the
tumor-associated fusobacteria is as passengers from the oral cavity rather than residential bacteria in
the colon.
5. Molecular Mechanistic Pathways Associated with in Fn-Positive CRC
Molecular pathology offers an opportunity to understand how Fn may contribute to the
carcinogenesis of CRC. An overview of the proposed pathways linking Fn to colorectal carcinogenesis
is presented in Figure 1. At least three molecular pathways have been described in colorectal-cancer
initiation and progression. The chromosomal instability (CIN) pathway is seen in both FAP and
sporadic CRC. It involves chromosomal abnormalities such as deletions, insertions, as well as a loss
of heterozygosity and KRAS mutations [33]. Hereditary nonpolyposis colorectal cancer (HNPCC)
involves the mutator phenotype/mismatch repair pathway with germline mutations in the hMLH1,
hMSH2, hMSH6, or PMS2 genes, and also presents with KRAS mutations [34].
The third hypermethylation phenotype sees a polyp as the precursor lesion to cancer.
Characteristics of the hyperplastic/serrated polyp pathway include genetic alterations, including
the hypermethylation of some CpG islands and BRAF mutations [35]. This alteration may result in the
hypermethylation of the promoter region of mismatch repair enzymes, such as MLH1 [36]. These are
all plausible mechanisms for the development of neoplasms, but data demonstrating the involvement
of Fn are limited.
Microsatellite instability (MSI) is a conspicuous pathological feature of CRC [37]. Studies have
demonstrated increased MSI in colorectal-cancer tissue with high Fn [24,25,38]. However, the sequence
of progression involving MSI and Fn is still unknown. One potential interpretation is that Fn
involvement in inflammation pathways recruits inflammatory cytokines and enhances the production
of reactive oxygen species (ROS) (Figure 1i). These inflammation/ROS signaling pathways reduce the
activity of mismatch-repair (MMR) protein, resulting in MSI.
Another important characteristic of chronic gut mucosal inflammation is the CpG island
methylator phenotype (CIMP). CpG island methylation reduces gene expression-suppressing
epigenetic events. A number of studies have found Fn to be present in high-CIMP CRC [21,24,38].
Interestingly, Tahara et al. (2014) found Fn-enriched CRC to be correlated with several genetic
Diseases 2018, 6, 109 4 of 10
characteristics, namely wild-type TP53, mutant CHD7/8, and increased somatic mutations.
The growing body of research has come to the belief that Fn may be associated with specific molecular
subsets of CRC.
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Aryl hydrocarbon receptor (AhR) ligands. AhR mediates the transcription of cytokines that regulate 
immune response and immune-response inhibition promotes tumor growth. 
6. Fn Virulence Proteins and Colorectal Carcinogenesis  
In the last decade, two outer membrane proteins from Fn, Fap2 and FadA, have been implicated 
in a bacterium-dependent tumor-invasion mechanism. Fn has been shown to invade human 
epithelial cells, activating β-catenin signaling and promoting the growth of CRC cells via the FadA 
adhesion virulence factor [39] (Figure 1ii). Gur et al. identified a transporter protein, Fap2 which they 
believe increases the invasive ability of CRC via suppression of the immune response [40]. It is 
believed the Fap2 virulence factor directly interacts with the checkpoint receptor TIGIT on natural-
killer (NK) cells and lymphocytes, suppressing the antitumor actions of lymphocytes (Figure 1iii,iv). 
Binding FadA to vascular endothelial cadherin may enhance beta-catenin signaling and the Wnt 
signaling pathway, and promote CRC carcinogenesis [39]. Toll-like receptor 4 (TLR4), a critical 
protein for bacteria lipopolysaccharide (LPS), is upregulated in intestinal inflammation and thought 
to mediate CRC initiation and progression [41]. Chen et al. found that both Fn and LPS extracted 
from Fn activate the beta-catenin transduction pathway in colorectal tumor cells via the TLR4/P-
PAK1 mediators [42].  
MicroRNA-21 (miR-21) was enriched in the colorectal tissue and serum of patients with 
ulcerative colitis and CRC. MiR-21 is a transcriptional modulator of cellular processes such as 
proliferation, differentiation, and apoptosis, but its link to CRC prognosis is unclear. Studies using 
Fn-infected colorectal-cancer mouse models have found that FN increases mi-R21 expression by 
activating TLR4 [43]. Some researchers haves suggested that ligands targeting miR-21 may have a 
role in inhibiting colitis-associated colon cancer (CAC) [44].  
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6. Fn Virulence Proteins and Colorectal Carcinogenesis
In the last decade, two outer m mbrane proteins from Fn, Fap2 and FadA, have been implicated
in a bacterium-dependent tumor-invasion mechanism. Fn has been shown to invade human epithelial
cells, activating β-catenin signaling and promoting the growth of CRC cells via the FadA adhesion
virulence factor [39] (Figure 1ii). Gur et al. identified a transporter protein, Fap2 which they believe
increases the invasive ability of CRC via suppression of the immune response [40]. It is believed the
Fap2 virulence factor directly interacts with the checkpoint receptor TIGIT on natural-killer (NK) cells
and lymphocytes, suppressing the antitumor actions of lymphocytes (Figure 1iii,iv).
Binding FadA to vascular endothelial cadherin may enhance beta-catenin signaling and the Wnt
signaling pathway, and promote CRC carcinogenesis [39]. Toll-like receptor 4 (TLR4), a critical protein
for bacteria lipopolysaccharide (LPS), is upregulated in intestinal inflammation and thought to mediate
CRC initiation and progression [41]. Chen et al. found that both Fn and LPS extracted from Fn activate
the beta-catenin transduction pathway in colorectal tumor cells via the TLR4/P-PAK1 mediators [42].
MicroRNA-21 (miR-21) was enriched in the colorectal tissue and serum of patients with ulcerative
colitis and CRC. MiR-21 is a transcriptional modulator of cellular processes such as proliferation,
differentiation, and apoptosis, but its link to CRC prognosis is unclear. Studies using Fn-infected
colorectal-cancer mouse models have found that FN increases mi-R21 expression by activating
TLR4 [43]. Some researchers haves suggested that ligands targeting miR-21 may have a role in
inhibiting colitis-associated colon cancer (CAC) [44].
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In summary, the beta-catenin/WNT transduction cascade seems to have a key role in Fn-mediated
colorectal carcinogenesis. Further research is needed to determine how Fn-virulence proteins relate to
colorectal carcinogenesis.
7. Fn, Inflammation and Immunity in CRC
Extensive evidence has established the role of inflammation as contributing to and increasing
the risk of CRC. Both inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, bring
an increased risk of cancer [12]. The complex signal exchange between the diverse members of the
gut microbiome and immune system is a challenge that computational biologists are taking on.
Schirmer et al. (2016) mapped the inflammatory cytokine production associated with bacteria [45].
Several studies using immunoassays in colorectal tissue and in vitro cultures demonstrate that
Fn infection increases the expression of inflammatory cytokines in tumor tissue, including IL-6, IL-8,
TNF-α, and Cox-2, and these cytokines are capable of promoting tumor development [39,46–48].
Ye et al. found that Fn can trigger the release of chemokine CCL20 in colorectal-cancer cells cultured
with Fn [49]. Moreover, Fn stimulates macrophage activation, migration, and tumor infiltration [49,50].
NF-κB, a transcription factor thought to have a critical role in tumor growth [51], is raised in
Fn-enriched CRC [43,46].
Fn, like many human bacterial pathogens, has been linked with immune suppression.
Fn suppresses the immune system by inducing cell death in human lymphocytes [50,52,53]. Mima et al.
observed inverse association between the amount of CD3+ T-cell density and Fn [25], while Park et al.
were unable to find any significant change in CD3+ T-cell density with varying Fn abundance [50].
Recent metabolomics studies have identified L-tryptophan (Trp) as an essential amino acid
that plays a role in the balance between intestinal immune response and gut-microbiota maintenance.
Bacteria in the gut, including Fn, metabolize Trp to indole, tryptamine, and skatole derivatives, with the
rate depending on the unique combination of catalytic enzymes present in a given microbiota [54].
They indirectly mitigate endogenous Trp metabolism in the body [55]. Furthermore, variations
in Trp metabolism have been shown to alter microbial proliferation and microbiota diversity [56].
Trp metabolites modulate serve as ligands of the Aryl hydrocarbon receptor (AhR), which is believed
to partly regulate inflammatory response in gut epithelial tissues. It has been proposed that excessive
degradation of AhR ligands results in the loss of control of intestinal immune response [57,58]
(Figure 1v). Similarly, intestinal inflammation was attenuated in mice following inoculation with
Lactobacillus strains capable of metabolizing Trp to produce AhR ligands [59].
Fn in conjunction with dysbiosis of the local gut microbiome is a contributing factor in the
proliferation of tumors. Therefore, it has been hypothesized that therapies that target bacteria to
modulate immune response are a promising route for antitumor immune therapy. Several recent
papers have demonstrated positive immunotherapy responses in people to specific varieties of gut
bacteria [60–62]. Translating these positive findings into meaningful clinical therapies requires teasing
out the mechanisms of the complex biological pathways outlined above.
8. Detection of Fn in CRC
Several different methods are used to detect Fn. These include conventional quantitative
polymerase chain reaction (qPCR), fluorescent quantitative PCR (FQ-PCR), metagenomic sequencing,
fluorescence in situ hybridization (FISH), 16S ribosomal RNA sequencing, and droplet digital PCR
(ddPCR) [63]. In addition, sample collection methods vary among studies, from formalin-fixed
paraffin-embedded CRC tissue, CRC frozen tissue, genomic DNA, and feces collected from CRC
patients. Among these detection methods, qPCR is the least expensive and most widely used.
The original 2011 studies that first demonstrated the association between Fn and CRC both used
sequencing-based methods to identify the bacteria. A 2018 replication study detected Fn in just 25%
of colorectal carcinomas, and the difference in the level of this species in colorectal carcinomas and
adjacent tissue was not significant [64]. The lack of replication may be due to differences in sample size:
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the replication study had 40 matched cases, while the original Casterellain study had 99 [15]. Technical
issues with qPCR might also have contributed to the variation in results [65]. The replication-study
results highlight the need for accurate Fn-detection methods, as well as prospective human studies.
9. Cause or Consequence
Whether Fn colonization is a cause or consequence of CRC is unknown. Experiments that
used daily doses of Fn in rodent models of colon cancer indicate that Fn acts in the early stages of
CRC, creating a proinflammatory environment that supports tumor progression [43,46]. However,
germfree mouse experiments involving the daily administration of two strains of Fn failed to
promote tumorigenesis, and therefore suggest that Fn on its own may not induce either inflammation
or cancer [66]. Meanwhile, other studies favor a role for Fn in the late stages of CRC [15,30].
The development of cancer is multifaceted, and the gut microbiome is a contributing factor.
10. Summary and Perspectives
The observations of the active role of the gut microbiome in tumorigenesis have resulted in an
energetic search for causative agents among normal flora bacteria. This is a plausible hypothesis
given the evidence of bacterial roles in chronic inflammatory disorders and related cancers. Studies
of genetically deficient rodent models demonstrate an association between Fn and CRC. This review
has identified studies that demonstrate the ability of Fn to colonize mucosal surfaces in the colon
and invade human epithelial cells, activate beta-catenin signaling, induce oncogenic gene expression,
and promote the growth of CRC cells.
Gut bacteria are implicated in carcinogenesis due to evidence of stimulating inflammatory
responses and suppressing host immune reactions to tumor growth. Two Fn surface-proteins, FadA
and Fap2, are thought to increase the virulence of Fn by facilitating it entering cells and contributing
to gene expression. Furthermore, gut bacterial activation of the WNT signaling pathway, the MSI
pathway, and of inflammatory responses in the host at the site of a tumor, suggest a contributory role
for Fn in CRC progression and a role of therapies targeting the gut microbiome to modulate the host
immune response to tumors. Further investigation of gut-microbiome metabolites is required to tease
out their role in complex signaling cascades regulating host immune responses to cancer.
However, the capacity for causing inflammation or cancers may depend on the summative
activities of multiple species in any given microbiota rather than on a single species. Another possible
explanation is that the host role is critical here. Human gene defects, in collaboration with a normal
bacterial microbiota, could in theory lead to cancer development in an individual over their lifetime.
Future investigations could seek to discover any relevant weak gene defects in human patients,
and correlate them with long-term pathogenesis. Whether Fn enrichment is a consequence or a
cause of carcinogenesis or inflammation in colorectal tissue remains to be elucidated. Prospective
studies could provide more definitive answers on the temporal order between Fn and CRC. Even
if Fn colonization is a consequence of CRC, it may still play an important role in enhancing tumor
malignancy, promoting metastasis, and evading antitumor immunity.
The role of Fn in tumorigenesis has thrown up some intriguing questions about cancer causes.
Cancer development could potentially be reduced by manipulating the bacterial microbiota using
probiotics, fecal implants, and antibiotic therapies or vaccination. Fecal Fn may be a favorable
measurable biological marker for CRC detection, but more research is needed, as it is unclear how it
varies throughout the stages of colorectal cancer. Therefore, considerably more work is needed on
host–bacteria crosstalk and the virulence proteins that are involved in colorectal carcinogenesis.
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